Serum endostatin and risk of mortality in the elderly: Findings from 2 community-based cohorts

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 11, 2013, Pages 2689-2695

  Ärnlöv, Johan ^a,b,c   Ruge, Toralph ^d   Ingelsson, Erik ^b   Larsson, Anders ^b   Sundström, Johan ^b   Lind, Lars ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c DALARNA UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

cardiovascular diseases; endostatin; epidemiology; extracelluler matrix proteins; mortality; neoplasms

Indexed keywords

ENDOSTATIN;

AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; ENDOSTATIN; EPIDEMIOLOGY; EXTRACELLULER MATRIX PROTEINS; MORTALITY; NEOPLASMS;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; ENDOSTATINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RESIDENCE CHARACTERISTICS; RISK FACTORS;

EID: 84887061695     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301704     Document Type: Article

References (61)

1. Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol. 2011;30:83-92.
2. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
3. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999;59:6052-6056.
4. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000;19:1187-1194.
5. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486:247-251.
6. Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkilä P, Rehn M, Sorsa T, Salo T, Pihlajaniemi T. Generation of biologically active end-ostatin fragments from human collagen XVIII by distinct matrix metal-loproteases. Exp Cell Res. 2005;307:292-304.
7. Veillard F, Saidi A, Burden RE, Scott CJ, Gillet L, Lecaille F, Lalmanach G. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem. 2011;286:37158-37167.
8. Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS. 2004;112:450-462.
9. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR. Endostatin inhibits VEGF-induced endo-thelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999;18:4414-4423.
10. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood. 2005;105:1044-1051.
11. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607.
12. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001;20:337-345.
13. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endo-thelial cells. Biochem Biophys Res Commun. 2007;361:79-84.
14. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR Jr, Libutti SK. Serum end-ostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000;6:4628-4634.
15. Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, Choyke PL, Libutti SK. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 2001;8:741-745.
16. Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK. Serum end-ostatin levels are elevated in patients with soft tissue sarcoma. Cancer. 2001;91:1525-1529.
17. Ohlund D, Ardnor B, Oman M, Naredi P, Sund M. Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int J Cancer. 2008;122:2805-2810.
18. Kuroi K, Tanaka C, Toi M. Circulating levels of endostatin in cancer patients. Oncol Rep. 2001;8:405-409.
19. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers. 2001;16:5-26.
20. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009;28:177-183.
21. Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F, Lichtenegger W, Sehouli J, Kümmel S. Prognostic signifcance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res. 2011;31:2651-2655.
22. Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kümmel S. Prognostic signifcance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011;31:2589-2595.
23. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One. 2010;5:e15003.
24. Kłubo-Gwiezdzinska J, Junik R, Kopczynska E. Serum endostatin levels in patients with metastatic and non-metastatic well-differentiated thyroid cancer. Endokrynol Pol. 2010;61:7-12.
25. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fbro-blast growth factor in melanoma patients during disease progression. Br J Dermatol. 2007;156:653-658.
26. Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett. 2004;204:87-95.
27. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer. 2003;97:2767-2775.
28. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003;61:719-723.
29. Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002;95:1637-1643.
30. Moulton KS, Olsen BR, Sonn S, Fukai N, Zurakowski D, Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation. 2004;110:1330-1336.
31. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neo-vascularization and plaque growth in apolipoprotein E-defcient mice. Circulation. 1999;99:1726-1732.
32. Zeng X, Chen J, Miller YI, Javaherian K, Moulton KS. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J Lipid Res. 2005;46:1849-1859.
33. Arenillas JF, Alvarez-Sabín J, Montaner J, Rosell A, Molina CA, Rovira A, Ribó M, Sánchez E, Quintana M. Angiogenesis in symptomatic intra-cranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke. 2005;36:92-97.
34. Seko Y, Fukuda S, Nagai R. Serum levels of endostatin, vascular endothe-lial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci (Lond). 2004;106:439-442.
35. Ramazani M, Lundin C, Sund M. Increased circulating levels of basement-membrane components in patients with abdominal aortic aneurysms-a pilot study. Eur J Vasc Endovasc Surg. 2011;42:484-487.
36. Mitsuma W, Kodama M, Hanawa H, Ito M, Ramadan MM, Hirono S, Obata H, Okada S, Sanada F, Yanagawa T, Kashimura T, Fuse K, Tanabe N, Aizawa Y. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol. 2007;99:494-498.
37. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metal-loproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Infamm. 2005;2005:144-149.
38. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol. 2004;43:1383-1387.
39. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol. 2005;25:2368-2375.
40. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol. 1998;18:258-264.
41. Navarro-Sobrino M, Rosell A, Hernández-Guillamon M, Penalba A, Boada C, Domingues-Montanari S, Ribó M, Alvarez-Sabín J, Montaner J. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis. 2011;216:205-211.
42. Iribarren C, Herrinton LJ, Darbinian JA, Tamarkin L, Malinowski D, Vogelman JH, Orentreich N, Baer D. Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race? Vasc Med. 2006;11:13-20.
43. Zhang J, Wang P, Huang YB, Li J, Zhu J, Luo X, Shi HM, Li Y. Plasma cathepsin L and its related pro/antiangiogenic factors play useful roles in predicting rich coronary collaterals in patients with coronary heart disease. J Int Med Res. 2010;38:1389-1403.
44. Ross R. Atherosclerosis is an infammatory disease. Am Heart J. 1999;138(5 Pt 2):S419-S420.
45. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307-310.
46. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf). 2011;203:279-286.
47. Savoia C, Schiffrin EL. Infammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-158.
48. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31.
49. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, Schwartz RS. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol. 2005;25:1119-1127.
50. Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G, Van Noorden CJ. Cathepsin L, target in cancer treatment? Life Sci. 2010;86:225-233.
51. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
52. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307.
53. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specifc tumor suppressors. Proc Natl Acad Sci USA. 2005;102:2934-2939.
54. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422-433.
55. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061.
56. Watorek E, Paprocka M, Dus D, Kopec W, Klinger M. Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. Pol Arch Med Wewn. 2011;121:296-301.
57. Bruserud O, Grovan F, Lindås R, Blymke Møinichen C, Osterhus KK. Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fbroblast growth factor, leptin and endostatin. Scand J Clin Lab Invest. 2005;65:505-511.
58. Gu JW, Gadonski G, Wang J, Makey I, Adair TH. Exercise increases endostatin in circulation of healthy volunteers. BMC Physiol. 2004;4:2.
59. Suhr F, Brixius K, de Marées M, Bölck B, Kleinöder H, Achtzehn S, Bloch W, Mester J. Effects of short-term vibration and hypoxia during high-intensity cycling exercise on circulating levels of angiogenic regulators in humans. J Appl Physiol. 2007;103:474-483.
60. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005;29:1308-1314.
61. Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swietoslawski J, Stepien H. Systemic blood osteopon-tin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine. 2011;55:56-61.